Printer Friendly

Grifols to distribute its saline product in the US via Henry Schein.

M2 PHARMA-March 6, 2018-Grifols to distribute its saline product in the US via Henry Schein


Healthcare company Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ:GRFS) announced on Monday the launch of a US distribution agreement for its saline product with Henry Schein (NASDAQ:HSIC).

Under the terms of the agreement, Henry Schein will market and distribute Grifol's 500ml Normal Saline solution (0.9% Sodium Chloride Injection, USP) in the US market.

Grifol's 500ml Normal Saline solution is manufactured at its industrial complex in Murcia (Spain) and has passed US FDA approval to market this product in the US in 2017.

This agreement marks an important step forward to mitigate the current shortage situation and represents for both companies new possibilities of future commercialization for other products manufactured in Grifols' Murcia and Barcelona facilities.

In 2018, Grifols will continue the expansion of its capacity in its industrial complex in Barcelona (Spain). The expansion includes two new production lines of IV solutions that will enable this plant to add production capacity by an additional 20m units to meet the increasing market demand for this type of product.

Both production plants in Murcia and Barcelona are reportedly accredited by the US FDA, among other regulating bodies, concluded Grifols.

((Comments on this story may be sent to

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:4EUSP
Date:Mar 6, 2018
Previous Article:Wize Pharma reports one for-24 reverse common stock split.
Next Article:Tenax Therapeutics Preclinical Studies Show Levosimendan Improves Right Heart Function.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters